首页 | 本学科首页   官方微博 | 高级检索  
检索        

植入式胶囊渗透压泵在大鼠脑梗死模型脑室给药中的应用
引用本文:包新杰,施浩,李雪元,左赋兴,关健,窦万臣,王任直.植入式胶囊渗透压泵在大鼠脑梗死模型脑室给药中的应用[J].医学研究杂志,2016,45(8):20-23.
作者姓名:包新杰  施浩  李雪元  左赋兴  关健  窦万臣  王任直
作者单位:100730 中国医学科学院/北京协和医学院北京协和医院神经外科;100730 中国医学科学院/北京协和医学院北京协和医院神经外科;100730 中国医学科学院/北京协和医学院北京协和医院神经外科;100730 中国医学科学院/北京协和医学院北京协和医院神经外科;100730 中国医学科学院/北京协和医学院北京协和医院神经外科;100730 中国医学科学院/北京协和医学院北京协和医院神经外科;100730 中国医学科学院/北京协和医学院北京协和医院神经外科
基金项目:国家自然科学基金资助项目(81200916);国家高技术研究发展计划(“863”计划)项目(2014AA020513,2013AA020106)
摘    要:目的 探讨植入式胶囊渗透压泵对大鼠脑梗死模型(middle cerebral artery occlusion, MCAO)进行脑室内给药的可行性。方法 18只改良神经损伤严重程度评分(modified neurological severity scores, mNSS)在10~13分的SD雄性大鼠随机分成3组:渗透压泵给药组、常规给药组和对照组,每组各6只大鼠。模型前和模型后24h、3、7和14天分别行mNSS评分;模型后14天处死大鼠行2,3,5-三苯氯化四氮唑(TTC)染色并计算脑梗死体积。结果 模型后14天,渗透压泵给药组和常规给药组大鼠神经功能明显改善,mNSS评分均低于对照组,差异有统计学意义(P<0.05);渗透压泵给药组大鼠神经功能的恢复程度优于常规给药组大鼠,差异有统计学意义(P<0.05)。渗透压泵给药组大鼠的脑梗死体积为28.6%±5.8%,低于常规给药组(35.5%±7.6%)和对照组(38.2%±6.5%),和对照组比较差异有统计学意义(P<0.05);常规给药组大鼠的脑梗死体积小于对照组,但差异无统计学意义(P>0.05)。结论 植入式胶囊渗透压泵应用于大鼠脑梗死模型的脑室给药是可行和有效的,这种缓释的给药方式显著优于单次脑室内给药方式。

关 键 词:脑梗死  渗透压泵  脑室给药
收稿时间:2016/1/25 0:00:00
修稿时间:2016/2/11 0:00:00

Application of Intraventricular Administration Using Osmotic Pumps for Middle Cerebral Artery Occlusion Models in Rats.
Bao Xinjie,Shi Hao,Li Xueyuan.Application of Intraventricular Administration Using Osmotic Pumps for Middle Cerebral Artery Occlusion Models in Rats.[J].Journal of Medical Research,2016,45(8):20-23.
Authors:Bao Xinjie  Shi Hao  Li Xueyuan
Institution:Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Abstract:Objective To investigate the feasibility of intraventricular administration using osmotic pumps for middle cerebral artery occlusion (MCAO) models in rats. Methods Eighteen rats with the modified neurological severity scores (mNSS) between 10 and 13 were randomly divided into three groups: (1) osmotic pump administration group(n=6); (2) regular administration group(n=6); (3) control group(n=6). The mNSS were tested before, 24h, 3days, 7days and 14days after MCAO. All rats were killed 24d after MCAO. The brains were removed and dissected into 6 pieces of 2 mm coronal sections. The fresh brain slices were stained by 2% 2,3,5-triphenyltintetrazolium chloride and relative infarct volume was measured. Results Fourteen days after MCAO, rats in osmotic pump administration group exhibited significant behavioral recovery compared with regular administration group and the control group (P<0.05). In addition, infarct volume of three groups was 28.6%±5.8% in osmotic pump administration group, 35.5%±7.6% in regular administration group, and 38.2%±6.5% in the control group. There was significant difference between osmotic pump administration group and the control group (P<0.05). Conclusion The application of intraventricular administration using osmotic pumps for MCAO models in rats is feasible and effective.
Keywords:Cerebral ischemia  Osmotic pump  Intraventricular administration
点击此处可从《医学研究杂志》浏览原始摘要信息
点击此处可从《医学研究杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号